Hannes Sabine, Abhari Behnaz Ahangarian, Fulda Simone
Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Komturstr. 3a, 60528 Frankfurt, Germany; General and Visceral Surgery, Goethe-University, Frankfurt, Germany.
Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Komturstr. 3a, 60528 Frankfurt, Germany.
Cancer Lett. 2016 Sep 28;380(1):31-8. doi: 10.1016/j.canlet.2016.05.036. Epub 2016 Jun 3.
Evasion of apoptosis represents a key mechanism of treatment resistance of pancreatic cancer (PC) and contributes to the poor prognosis of this cancer type. Here, we report that induction of necroptosis is an alternative strategy to trigger programmed cell death in apoptosis-resistant PC cells. We show that the second mitochondrial activator of caspases (Smac) mimetic BV6 that antagonizes inhibitor of apoptosis (IAP) proteins induces necroptosis in PC cells in which apoptosis is blocked by the caspase inhibitor zVAD.fmk. Intriguingly, BV6 switches autocrine/paracrine production of tumor necrosis factor (TNF)α by PC cells into a death signal and also acts in concert with exogenously supplied TNFα to trigger necroptosis, when caspase activation is simultaneously blocked. BV6 stimulates TNFα production and formation of the receptor-interacting protein (RIP)1/RIP3-containing necrosome complex in PC cells. Knockdown of TNF receptor 1 (TNFR1) protects PC cells from BV6- or BV6/TNFα-mediated cell death, demonstrating that TNFα autocrine/paracrine signaling by PC cells contributes to BV6-induced necroptosis. Importantly, genetic silencing of receptor interacting protein kinase 3 (RIPK3) or mixed lineage kinase domain-like protein (MLKL) significantly rescues PC cells from BV6- or BV6/TNFα-induced cell death. Similarly, pharmacological inhibition of RIP1, RIP3 or MLKL significantly reduces BV6- or BV6/TNFα-stimulated cell death. By demonstrating that Smac mimetics can bypass resistance to apoptosis by triggering necroptosis as an alternative form of programmed cell death, our findings have important implications for the design of new treatment concepts for PC.
逃避细胞凋亡是胰腺癌(PC)治疗耐药的关键机制,并且导致了这种癌症类型的不良预后。在此,我们报道诱导坏死性凋亡是在凋亡抗性PC细胞中触发程序性细胞死亡的一种替代策略。我们表明,拮抗凋亡抑制蛋白(IAP)的第二线粒体促凋亡蛋白(Smac)模拟物BV6在PC细胞中诱导坏死性凋亡,其中凋亡被半胱天冬酶抑制剂zVAD.fmk阻断。有趣的是,当半胱天冬酶激活同时被阻断时,BV6将PC细胞自分泌/旁分泌的肿瘤坏死因子(TNF)α转化为死亡信号,并且还与外源性提供的TNFα协同作用以触发坏死性凋亡。BV6刺激PC细胞中TNFα的产生以及含受体相互作用蛋白(RIP)1/RIP3的坏死小体复合物的形成。敲低TNF受体1(TNFR1)可保护PC细胞免受BV6或BV6/TNFα介导的细胞死亡,表明PC细胞的TNFα自分泌/旁分泌信号传导促成了BV6诱导的坏死性凋亡。重要的是,受体相互作用蛋白激酶3(RIPK3)或混合谱系激酶结构域样蛋白(MLKL)的基因沉默显著挽救PC细胞免受BV6或BV6/TNFα诱导的细胞死亡。同样,对RIP1、RIP3或MLKL的药理学抑制显著降低BV6或BV6/TNFα刺激的细胞死亡。通过证明Smac模拟物可以通过触发坏死性凋亡作为程序性细胞死亡的一种替代形式来绕过对凋亡的抗性,我们的发现对PC新治疗概念的设计具有重要意义。